943
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene

, , , , , & show all
Pages 1815-1817 | Received 25 Feb 2011, Accepted 07 Apr 2011, Published online: 17 May 2011

References

  • Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma: results from the Non-Hodgkin’s Lymphoma classification project. Ann Oncol 2002;13:140–149.
  • Greer JP. Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 2006:331–337.
  • Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79:1789–1795.
  • Steinberg AD, Seldin MF, Jaffe ES, et al. NIH conference. angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 1988;108:575–584.
  • Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.
  • Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218–224.
  • Tsai DE, Aqui NA, Vogl DT, et al. Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 2005;5:2070–2073.
  • Boehm M, Zhang M, Badea B, et al. Synthesis and structure-activity relationship of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930–2941.
  • Duvic M, Hymes K, Hearld P, et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456–2471.
  • Tsai DE, Luger SM, Andreadis C, et al. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res 2008;14:5619–5625.
  • Esteva F, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003;21:999–1006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.